WuXi AppTec, Hengrui Pharmaceutical, and other 8 stocks have a net inflow of more than 60 million yuan

【Pharmaceutical Network Pharmaceutical Stock Market】 On December 29, Shenwan's industry rose 4, and the top rising industry was pharmaceutical biology, with an increase of 1.
72%.

From the perspective of funds, the main funds of the two cities had a net outflow of 14.
967 billion yuan throughout the day, and there were only 3 industries with a net inflow of main funds, of which the pharmaceutical and biological industry had a net inflow of 333 million yuan
.
According to the statistics of capital flow data, there are 254 stocks with a net inflow of funds in the pharmaceutical and biological industry, of which 8 have a net inflow of more than 60 million yuan, including WuXi AppTec, Hengrui Pharmaceutical, Kangbei, Kailaiying, Boteng, Kelun Pharmaceutical, Sunflower Pharmaceutical, and Junshi Biologics
.
On December 29, WuXi AppTec had a net inflow of 164.
8632 million yuan According to the data, WuXi AppTec's main business covers CRO, chemical drug CDMO, cell and gene therapy CTDMO, and its revenue mainly comes from chemical business and testing business, and the chemical business accounts for more than 70%
of the revenue 。 Data show that in the first three quarters of 2022, WuXi AppTec had orders in hand of more than 35 billion yuan, with more than 1,000 new customers, covering 20 major pharmaceutical companies, and revenue from 20 major pharmaceutical companies of 12.
918 billion yuan, a year-on-year increase of 175%; Revenue from US customers increased by 110% to RMB18.
991 billion, and revenue from Chinese customers increased by 30% to RMB5.
318 billion; The revenue from original customers was 27.
546 billion yuan, an increase of 80%, the income from new customers was 849 million yuan, and the overseas income accounted for more than
80%.
WuXi AppTec adjusted its previously expected revenue growth target for the full year of 2022 from 68%~72% to 70%~72%, maintaining a compound revenue growth rate of no less than 34% from 2021 to 2024
.
On December 29, Hengrui Pharmaceutical's net inflow of funds was 145.
4038 million yuan It is understood that Hengrui Pharmaceutical has always adhered to the development strategy of scientific and technological innovation, committed to the research and development of innovative drugs for more than 20 years, and continued to increase investment
in innovative research and development.
R&D investment continued to maintain rapid growth, with an average annual growth of about
30%.
Hengrui Pharmaceutical has accumulated strong innovation strength and fruitful innovation results, it has a total of 8 innovative drugs listed in China, the number of innovative drugs under research is high, more than 50 innovative drugs are under clinical development, more than 240 clinical trials are carried out at home and abroad, and a number of independent intellectual property rights and technology platforms have been built, covering cutting-edge technical fields, forming an echeloned product pipeline
.
On December 29, Combe had a net inflow of 102.
8429 million yuan According to the data, Kangbei's main business is engaged in the research and development, manufacturing, wholesale and distribution of drugs and health products
.
According to the third quarter report of Kangbei in 2022, the company's main revenue was 4.
488 billion yuan, down 8.
68% from the same period last year; Net profit attributable to owners was RMB229 million, up 4.
49%
year-on-year.
Kangbei recently said in an institutional survey that with the superposition of policy expectations in the high cold season, the company's demand for cold drugs has increased, in addition, the company's antipyretic and analgesic drugs, cough and phlegm products, dietary supplements, etc.
have also entered a new period of epidemic home prevention and control in the country, sales have increased to a certain extent, and the company expects that the business performance of self-care products in the fourth quarter of this year is better
。 On December 29, Kaileying had a net inflow of 84.
5981 million yuan According to the data, Kaileying is a domestic small molecule CDMO enterprise, the company is mainly committed to providing one-stop CMC services and R&D and production services for the whole life cycle of drugs for domestic and foreign pharmaceutical companies and biotechnology companies, so as to accelerate the clinical research and commercial application
of innovative drugs 。 According to the third quarter report of Kaileying in 2022, the company's main revenue was 7.
812 billion yuan, an increase of 167.
25% over the same period last year; the net profit attributable to the parent was 2.
721 billion yuan, an increase of 291.
58% year-on-year; Non-net profit was RMB2.
683 billion, up 350.
16% year-on-year; Among them, in the third quarter of 2022, the company's main revenue in a single quarter was 2.
77 billion yuan, a year-on-year increase of 138.
25%; The net profit attributable to owners in a single quarter was 981 million yuan, a year-on-year increase of 269.
4%.

In addition to the above enterprises, on December 29, the net inflow of Boton shares was 72.
7792 million yuan, the net inflow of Kelun Pharmaceutical was 71.
2876 million yuan, the net inflow of Sunflower Pharmaceutical was 66.
458 million yuan, and the net inflow of Junshi Biotech was 61.
8785 million yuan
.
The net inflows of CanSino, Lukang Pharmaceutical, Sunward Pharmaceutical, ST Kangmei and Aier Ophthalmology were 58.
4182 million yuan, 57.
7323 million yuan, 57.
3473 million yuan, 55.
3045 million yuan and 53.
2784 million yuan respectively
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.